A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41

[1]  Baoshan Zhang,et al.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges , 2015, Nature.

[2]  D. Dimitrov,et al.  Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains , 2013, Journal of Virology.

[3]  Liang Xu,et al.  Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. , 2012, Chemical communications.

[4]  Liang Xu,et al.  Interactions between different generation HIV‐1 fusion inhibitors and the putative mechanism underlying the synergistic anti‐HIV‐1 effect resulting from their combination , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Hong Lu,et al.  A Novel Chimeric Protein-based HIV-1 Fusion Inhibitor Targeting gp41 Glycoprotein with High Potency and Stability* , 2011, The Journal of Biological Chemistry.

[6]  Hong Lu,et al.  Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains , 2009, Journal of Virology.

[7]  Shibo Jiang,et al.  Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains as Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors* , 2008, Journal of Biological Chemistry.

[8]  A. Debnath,et al.  Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs , 2008, Biochemical and Biophysical Research Communications.

[9]  Shibo Jiang,et al.  Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide , 2007, Cell.

[10]  Y. Shai,et al.  The role of the N-terminal heptad repeat of HIV-1 in the actual lipid mixing step as revealed by its substitution with distant coiled coils. , 2005, Biochemistry.

[11]  Y. Shai,et al.  How structure correlates to function for membrane associated HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. , 2003, Journal of molecular biology.

[12]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[13]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[14]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[15]  P. S. Kim,et al.  A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. , 1997, Journal of biomolecular structure & dynamics.

[16]  Philip E. Dawson,et al.  Modulation of Reactivity in Native Chemical Ligation through the Use of Thiol Additives , 1997 .

[17]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[18]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Jiang,et al.  Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. , 1993, Biochemical and biophysical research communications.

[20]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[21]  Shibo Jiang,et al.  HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. , 2007, Current pharmaceutical design.

[22]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[23]  T. Muir,et al.  Synthesis of proteins by native chemical ligation. , 1994, Science.